CS logo
small CS logo
Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi

Bologna, Italy
Corporate office
Padiglione 8, Via Giuseppe Massarenti, 9, 40138 Bologna BO

About Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi


  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Gruppo Italiano Malattie EMatologiche dell'Adulto
41
Fondazione Italiana Linfomi ONLUS
10
University of Bologna
6
Hoffmann-La Roche
5
Incyte Corporation
4
Seagen Inc.
4
Celgene
3
Janssen Research & Development, LLC
3
Fondazione Italiana Sindromi Mielodisplastiche-ETS
2
Gruppo Italiano Trapianto di Midollo Osseo
2
Pfizer
2
Total Rows: 21

Clinical Trials at Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi


During the past decade, Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi conducted 40 clinical trials. In the 10-year time frame, 40 clinical trials started and 19 clinical trials were completed, i.e. on average, 47.5% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 3 clinical trials were completed. i.e. 25% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years3344448899557722221144770033Started TrialsCompleted Trails20152016201720182019202020210510
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
2003-02-01
2013-08-01
Completed
470
Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
2003-03-01
Unknown status
STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia
2001-12-01
2011-02-01
Completed
105
Treatment of Adult Ph+ LAL With BMS-354825
2006-09-01
2008-09-01
Completed
53
Velcade in Myelodysplastic Syndrome - Pilot Study
2006-08-01
2008-03-01
Terminated
28
Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma
2006-02-01
2009-01-01
Completed
499
Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia
2007-03-01
2014-07-01
Completed
57
Safety, Tolerability, and Efficacy of Deferasirox in MDS
2007-06-01
2013-11-01
Completed
158

Rows per page:

1–92 of 92

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 41 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 10 trials sponsored, "University of Bologna" with 6 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored and "Incyte Corporation" with 5 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 21 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi" #1 collaborator was "Millennium Pharmaceuticals, Inc." with 3 trials as a collaborator, "AbbVie" with 2 trials as a collaborator, "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 2 trials as a collaborator, "Novartis" with 2 trials as a collaborator and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.
Created with Highcharts 11.1.0Top Leading SponsorsGruppo Italiano MalattieEMatologichedell'Adulto: 41Gruppo Italiano MalattieEMatologichedell'Adulto: 41Fondazione ItalianaLinfomi ONLUS: 10Fondazione ItalianaLinfomi ONLUS: 10University of Bologna: 6University of Bologna: 6Hoffmann-La Roche: 5Hoffmann-La Roche: 5Incyte Corporation: 4Incyte Corporation: 4Seagen Inc.: 4Seagen Inc.: 4Celgene: 3Celgene: 3Janssen Research &Development, LLC: 3Janssen Research &Development, LLC: 3Fondazione ItalianaSindromiMielodisplastiche-ETS: 2Fondazione ItalianaSindromiMielodisplastiche-ETS: 2Gruppo ItalianoTrapianto di MidolloOsseo: 2Gruppo ItalianoTrapianto di MidolloOsseo: 2

Created with Highcharts 11.1.0Top CollaboratorsMillenniumPharmaceuticals, Inc.: 3MillenniumPharmaceuticals, Inc.: 3AbbVie: 2AbbVie: 2Centro di Riferimentoper l'Epidemiologia e laPrev. OncologicaPiemonte: 2Centro di Riferimentoper l'Epidemiologia e laPrev. OncologicaPiemonte: 2Novartis: 2Novartis: 2Acceleron Pharma Inc.(a wholly ownedsubsidiary of MerckSharp and Dohme, asubsidiary of Merck &Co., Inc.): 1Acceleron Pharma Inc.(a wholly ownedsubsidiary of MerckSharp and Dohme, asubsidiary of Merck &Co., Inc.): 1Azienda Policlinico Umberto I: 1Azienda Policlinico Umberto I: 1Central EuropeanMyeloma Study Group:1Central EuropeanMyeloma Study Group:1DSMM (DeutscheStudiengruppe MultiplesMyelom): 1DSMM (DeutscheStudiengruppe MultiplesMyelom): 1European Myeloma Network: 1European Myeloma Network: 1Gruppo Italiano MalattieEMatologichedell'Adulto: 1Gruppo Italiano MalattieEMatologichedell'Adulto: 1

Clinical Trials Conditions at Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi


According to Clinical.Site data, the most researched conditions in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi" are "Chronic Myeloid Leukemia" (7 trials), "Leukemia" (7 trials), "Acute Myeloid Leukemia" (6 trials), "Acute Lymphoblastic Leukemia" (5 trials) and "Multiple Myeloma" (5 trials). Many other conditions were trialed in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi" in a lesser frequency.

Clinical Trials Intervention Types at Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi


Most popular intervention types in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi" are "Drug" (71 trials), "Other" (12 trials), "Procedure" (3 trials), "Biological" (2 trials) and "Genetic" (2 trials). Other intervention types were less common.
The name of intervention was led by "Rituximab" (4 trials), "Venetoclax" (4 trials), "brentuximab vedotin" (4 trials), "Ibrutinib" (3 trials) and "Imatinib" (3 trials). Other intervention names were less common.

Clinical Trials Genders at Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi


The vast majority of trials in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi" are 90 trials for "All" genders and 2 trials for "Female" genders.

Clinical Trials Status at Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi


Currently, there are NaN active trials in "Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi". undefined are not yet recruiting, 17 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 47 completed trials in Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi, undefined suspended trials, and 7 terminated clinical trials to date.
Out of the total trials that were conducted in Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi, 5 "Phase 1" clinical trials were conducted, 46 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 2: 46Phase 2: 46Phase 3: 20Phase 3: 20Phase 1: 5Phase 1: 5Not Applicable: 4Not Applicable: 4Phase 4: 1Phase 4: 1

Created with Highcharts 11.1.0Trials StatusCompleted: 47Completed: 47Recruiting: 17Recruiting: 17Active, not recruiting: 13Active, not recruiting: 13Unknown status: 8Unknown status: 8Terminated: 7Terminated: 7